Kaplan-Meier estimates for duration of response and survival. (A) Duration of CR + CRh response (n = 15). (B) EFS in the adult efficacy-evaluable population (n = 64). (C) OS in the adult efficacy-evaluable population (n = 64). ∗EFS was defined as the number of months from the date of first dose to the date of first documented relapse/progression or death, whichever occurred first. †OS was defined as the percentage of at-risk patients who did not experience an event of death up to that time point. EFS, event-free survival.